Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Liu, Dongyang; Zhang, Li; Wu, Yiwen; Jiang, Ji; Tan, Fenlai; Wang, Yingxiang; Liu, Yong; Hu, Pei
• Is Part Of: Lung cancer. Volume 89:Issue 3(2015:Sep.)
• Page Start: 262
• Page End: 267
• Publication Date: 2015-09
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.05.024
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Icotinib exhibited good safety and preliminary anti-tumor activity in Chinese NSCLC patients.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Full pharmacokinetics of icotinib and its metabolites were firstly characterized in NSCLC patients.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">OBD was recommended to be 125 mg t.i.d. for the later clinical study.</p> </list-item> </list> </p> </sec> </abstract>